New Medicon Pharma Lab Profile
Key Indicators
- Authorised Capital ₹ 1.20 Cr
as on 05-07-2024
- Paid Up Capital ₹ 5.73 M
as on 05-07-2024
- Company Age 18 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.98 Cr
as on 05-07-2024
- Satisfied Charges ₹ 5.50 M
as on 05-07-2024
- Revenue -24.43%
(FY 2023)
- Profit -63.11%
(FY 2023)
- Ebitda 143.77%
(FY 2023)
- Net Worth 8.14%
(FY 2023)
- Total Assets 2.48%
(FY 2023)
About New Medicon Pharma Lab
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.20 Cr and a paid-up capital of Rs 5.73 M.
The company currently has active open charges totaling ₹1.98 Cr. The company has closed loans amounting to ₹5.50 M, as per Ministry of Corporate Affairs (MCA) records.
Selvaraj Kumar and Harinath Harinath serve as directors at the Company.
- CIN/LLPIN
U51397TN2006PTC059372
- Company No.
059372
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Mar 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does New Medicon Pharma Lab Private Limited offer?
New Medicon Pharma Lab Private Limited offers a wide range of products and services, including Fertility Enhancer, Injectable Products, Pharmaceutical Injectables, Anticoagulant and Antiplatelet Drugs, Enoxaparin Injection, TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Cardiac Drugs, Clexane Injection.
Who are the key members and board of directors at New Medicon Pharma Lab?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Selvaraj Kumar  | Director | 30-Mar-2007 | Current |
| Harinath Harinath | Director | 30-Mar-2006 | Current |
Financial Performance of New Medicon Pharma Lab.
New Medicon Pharma Lab Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 24.43% decrease. The company also saw a substantial fall in profitability, with a 63.11% decrease in profit. The company's net worth moved up by a moderate rise of 8.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of New Medicon Pharma Lab?
In 2023, New Medicon Pharma Lab had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
M Sea Pharmaceuticals Private LimitedActive 9 years 8 monthsSelvaraj Kumar and Harinath Harinath are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 29 Jun 2021 | ₹1.98 Cr | Open |
Indian Bank Creation Date: 12 Jun 2007 | ₹5.50 M | Satisfied |
How Many Employees Work at New Medicon Pharma Lab?
New Medicon Pharma Lab has a workforce of 4 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of New Medicon Pharma Lab, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped New Medicon Pharma Lab's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
